Search

Displaying results 3341 - 3350 of 7063 in total
  1. Drug

    Clormecaine

    go.drugbank.com/drugs/DB21148
    Experimental

    Clormecaine is a small molecule drug. The usage of the INN stem '-caine' in the name indicates that Clormecaine is a local anaesthetic. Clormecaine has a monoisotopic molecular weight of 242.08 Da.

  2. Drug

    Amezepine

    go.drugbank.com/drugs/DB21155
    Experimental

    Amezepine is a small molecule drug. The usage of the INN stem '-zepine' in the name indicates that Amezepine is a tricyclic compound. Amezepine has a monoisotopic molecular weight of 264.16 Da.

  3. Drug

    Phenacaine

    go.drugbank.com/drugs/DB21274
    Experimental

    Phenacaine is a small molecule drug. The usage of the INN stem '-caine' in the name indicates that Phenacaine is a local anaesthetic. Phenacaine has a monoisotopic molecular weight of 298.17 Da.

  4. Drug

    Uldazepam

    go.drugbank.com/drugs/DB21290
    Experimental

    Uldazepam is a small molecule drug. The usage of the INN stem '-azepam' in the name indicates that Uldazepam is a diazepam derivative. Uldazepam has a monoisotopic molecular weight of 359.06 Da.

  5. Drug

    Fluradoline

    go.drugbank.com/drugs/DB21333
    Experimental

    Fluradoline is a small molecule drug. The usage of the INN stem '-adol/-adol-' in the name indicates that Fluradoline is a analgesic. Fluradoline has a monoisotopic molecular weight of 301.09 Da.

  6. Drug

    Pinoxepin

    go.drugbank.com/drugs/DB21397
    Experimental

    Pinoxepin is a small molecule drug. The usage of the INN stem '-oxepin' in the name indicates that Pinoxepin is a tricyclic compound. Pinoxepin has a monoisotopic molecular weight of 398.18 Da.

  7. Drug

    Ruzadolane

    go.drugbank.com/drugs/DB21444
    Experimental

    Ruzadolane is a small molecule drug. The usage of the INN stem '-adol/-adol-' in the name indicates that Ruzadolane is a analgesic. Ruzadolane has a monoisotopic molecular weight of 375.13 Da.

  8. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment … [A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer.

  9. Drug

    Flotufolastat F-18

    go.drugbank.com/drugs/DB17851
    ApprovedInvestigational

    , and a high level of accumulation in tumors. … Unlike <sup>68</sup>Ga-labeled PSMA-targeting ligands, <sup>18</sup>F-labeled compounds targeting this protein have a longer half-life and can be produced in larger batches.

  10. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the